Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IG-HD01
- Development stage
- Preclinical
- Lead developer
- Incisive Genetics
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies, Gene Addition/Replacement → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
IG-HD01 is an allele-specific gene editing therapeutic being developed by Incisive Genetics for the treatment of Huntington's Disease. The drug utilizes a CRISPR-Cas9 ribonucleoprotein (RNP) complex delivered via lipid nanoparticles (LNPs), a non-viral approach designed to overcome the limitations of viral vectors. IG-HD01 is specifically engineered to target a single nucleotide polymorphism (SNP 1) associated with the mutant huntingtin (HTT) allele. By selectively inactivating the mutant allele while sparing the wild-type HTT gene, the therapy aims to reduce the production of the neurotoxic huntingtin protein that drives disease progression. As of early 2024, IG-HD01 is in the IND-enabling stage of development.
02
Targets
HTT (Huntingtin protein)
Beyond the preview
Go deeper on IG-HD01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IG-HD01.